eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2025-12-30 22 4 1725 1745 10.13005/bbra/3472 57149 article Arpana Patil 1 Mayuri Nazirkar 1 Kiran Thorat 1 Ubed Kothali 1 Department of Pharmaceutics, Smt. Kashibai Navale College of Pharmacy, Pune, India. Dolutegravir (DTG), classified as an integrase strand transfer inhibitor received regulatory approval in 2013, prevents immunodeficiency and reduces transmission risk. DTG demonstrates high permeability but limited solubility in aqueous medium. The present investigation designed to improve its solubility and rate of dissolution by formulating as liquisolid compact for oral route. Capmul MCM:Tween 20 (1:1) is used as a non-volatile liquid vehicle based on DTG solubility whereas based on liquid retention factor Neusilin UFL2 as carrier material and Aerosil 300 as coating material were selected.. The effect of % drug concentration in non-volatile solvent and ratio of carrier:coating on solubility and various dissolution parameters (Q₁₀, T₅₀ and Q₆₀) were systemically optimized through 3² full-factorial design. Polynomial equations and surface response graphs served to illustrate the influence of independent variables. In-vitro DTG release was superior from liquisolid compact tablets than pure drug as reflected from Mean Dissolution Time, Mean Dissolution Rate and Dissolution Efficiency values due to improved contact angle, wetting and drug surface area. FTIR results showed no drug-excipient interaction, while DSC and PXRD suggested loss of DTG crystallinity, indicating molecular dispersion of DTG. The liquisolid approach proved promising in promoting solubility and dissolution characteristics of Dolutegravir, a Biopharmaceutical Classification System (BCS) class II drug. https://www.biotech-asia.org/vol22no4/liquisolid-compact-based-strategy-for-augmented-solubility-and-dissolution-profile-of-dolutegravir-sodium/ Aerosil 300; Dolutegravir; Dissolution rate; Dissolution parameters; Liquisolid compact; Neusilin UFL2